Previous Close | 14.47 |
Open | 14.48 |
Bid | 14.47 x 200 |
Ask | 14.49 x 300 |
Day's Range | 14.35 - 14.63 |
52 Week Range | 11.32 - 16.86 |
Volume | |
Avg. Volume | 668,741 |
Market Cap | 915.531M |
Beta (5Y Monthly) | 0.57 |
PE Ratio (TTM) | 6.58 |
EPS (TTM) | 2.20 |
Earnings Date | May 07, 2024 - May 13, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | Sept 08, 2015 |
1y Target Est | 15.00 |
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it has entered into a secured credit agreement with Innoviva Strategic Opportunities LLC, a wholly-owned subsidiary of Innoviva, Inc. (Nasdaq: INVA) (collectively, "Innoviva"), Armata's largest shareholder. The gross proceeds to be received by the C
Company Sees 35% Year-Over-Year Growth in Q4 Product Revenues
BURLINGAME, Calif., February 29, 2024--Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today reported financial results for the fourth quarter and full year ended December 31, 2023 and highlighted select corporate achievements.